USD
+$0.00
(+0.00%
)At Close (As of Sep 26, 2025)
$168.53M
Market Cap
2.736
P/E Ratio
0.53
EPS
$2.43
52 Week High
$0.66
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $149M |
Total Revenue | $267M |
Cost Of Revenue | $118M |
Costof Goods And Services Sold | $118M |
Operating Income | -$112M |
Selling General And Administrative | $140M |
Research And Development | $93M |
Operating Expenses | $261M |
Investment Income Net | - |
Net Interest Income | -$27M |
Interest Income | - |
Interest Expense | $27M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $5.3M |
Income Before Tax | $29M |
Income Tax Expense | $29M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $29M |
Comprehensive Income Net Of Tax | - |
Ebit | $56M |
Ebitda | $61M |
Net Income | $29M |
Field | Value (USD) |
---|---|
Total Assets | $449M |
Total Current Assets | $342M |
Cash And Cash Equivalents At Carrying Value | $126M |
Cash And Short Term Investments | $126M |
Inventory | $70M |
Current Net Receivables | $122M |
Total Non Current Assets | $107M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $54M |
Intangible Assets Excluding Goodwill | $54M |
Goodwill | $0 |
Investments | - |
Long Term Investments | - |
Short Term Investments | $0 |
Other Current Assets | $23M |
Other Non Current Assets | - |
Total Liabilities | $581M |
Total Current Liabilities | $283M |
Current Accounts Payable | $28M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $4.5M |
Total Non Current Liabilities | $298M |
Capital Lease Obligations | $5M |
Long Term Debt | $265M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $270M |
Other Current Liabilities | $250M |
Other Non Current Liabilities | $28M |
Total Shareholder Equity | -$132M |
Treasury Stock | - |
Retained Earnings | -$1.6B |
Common Stock | $12K |
Common Stock Shares Outstanding | $115M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$20M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $5.3M |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | -$32M |
Profit Loss | - |
Cashflow From Investment | $230M |
Cashflow From Financing | -$187M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $29M |
Field | Value (USD) |
---|---|
Gross Profit | $149M |
Total Revenue | $267M |
Cost Of Revenue | $118M |
Costof Goods And Services Sold | $118M |
Operating Income | -$112M |
Selling General And Administrative | $140M |
Research And Development | $93M |
Operating Expenses | $261M |
Investment Income Net | - |
Net Interest Income | -$27M |
Interest Income | - |
Interest Expense | $27M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $5.3M |
Income Before Tax | $29M |
Income Tax Expense | $29M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $29M |
Comprehensive Income Net Of Tax | - |
Ebit | $56M |
Ebitda | $61M |
Net Income | $29M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Coherus BioSciences Inc. is a leading biopharmaceutical company specializing in the development and commercialization of biosimilars and innovative immuno-oncology therapies, primarily targeting the U.S. market. Based in Redwood City, California, Coherus aims to enhance patient access to high-quality biologics while driving down healthcare costs. With a robust pipeline and strategic collaborations, the company is positioned to capitalize on the growing demand for affordable treatment options in the oncology and autoimmune disease sectors.